Robust human genetic evidence supporting causal effects of FGF21 on reducing alcohol consuming behaviours
This study identifies a genetic instrument for FGF21 effects to provide causal human evidence supporting favourable effects of FGF21 analogues for the treatment of AUD and related traits, as well as on metabolic outcomes more broadly. Further clinical study is duly warranted.
Authors
- Héléne T. Cronjé (ORCID: https://orcid.org/0000-0001-6855-8324)
- M. Vujkovic
- R. Butt
- Rachel Gurrell
- Sile Hu
- Richard Mason
- Susanna C. Larsson
- Dipender Gill
Institutions
- Uppsala University (SE)
- University of Cambridge (GB)
- Karolinska Institutet (SE)
- Aptevo Therapeutics (United Kingdom) (GB)
- Translational Therapeutics (United States) (US)
- Philadelphia VA Medical Center (US)
- Sequoia (United States) (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- BMC Medicine
- Published
- 2026-03-23
- DOI
- https://doi.org/10.1186/s12916-026-04807-x
- Primary Topic
- Fibroblast Growth Factor Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00